In terms of Regulation 29 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that a meeting of the Board of Directors of the Company will be held on Thursday, August 3, 2023, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2023. This is further to informed that with reference to our letter dated June 28, 2023 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company’s Code of Conduct for Prevention of Insider Trading, the 'Trading Window’ for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Unaudited Financial Results for the quarter ended June 30, 2023.
The above information is a part of company’s filings submitted to BSE.